Is Journey Medical Corp (DERM) overvalued? · rev $56.1M
Journey Medical Corp (DERM) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Journey Medical Corp (DERM) looks expensive on cached numbers — not a short thesis.
Latest reported DERM revenue for 2024-12-31 was $56.1M. Net income was -$14.7M. Revenue was down 29.1% from 2023-12-31 to 2024-12-31. DERM currently screens at market cap $163.1M.
DERM currently screens at market cap $163.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DERM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DERM stock page for the full model, not this heading.
Not investment advice.